ACSM-ACS Cancer Exercise Specialist Course Free Sample Questions

This statement is true. The fundamental biological distinction between benign and malignant tumors is their potential for metastasis. Benign tumors are typically well-encapsulated, grow locally, and do not invade surrounding tissues or spread to distant sites. Malignant tumors, however, are characterized by uncontrolled cell division, local tissue invasion, and the ability to metastasize (spread) to distant organs via the lymphatic or circulatory systems. Understanding this distinction is critical for exercise specialists when reviewing a client's medical history.

In the TNM staging system, 'M1' indicates the presence of distant metastasis. For an ACSM-ACS Cancer Exercise Specialist, this is the most critical piece of information because breast cancer frequently metastasizes to the bone. The presence of bone metastases drastically alters the exercise prescription by introducing absolute or relative contraindications to heavy skeletal loading, high-impact activities, and extreme ranges of motion to prevent pathological fractures.

This is the optimal and safest approach. Following a mastectomy and axillary lymph node dissection, early goals must prioritize restoring functional ROM through gentle active and active-assisted movements, not aggressive stretching or heavy lifting. Because radiation therapy (EBRT) often causes further tissue fibrosis and restricts mobility, improving ROM before and during radiation is critical. Concurrently, utilizing lower-body resistance training and moderate aerobic exercise safely addresses her goal of rebuilding systemic strength and managing fatigue without overstressing the healing surgical site. The lymph node dissection also puts her at risk for lymphedema, requiring careful monitoring.

Anthracyclines (such as doxorubicin) are notorious for causing dose-dependent, potentially irreversible cardiotoxicity. Exercise specialists must be aware of this history to properly monitor for signs of cardiac distress.

Trastuzumab (Herceptin), a HER2-targeted monoclonal antibody, is highly associated with cardiotoxicity, particularly when given after or alongside anthracyclines. This often presents as a reversible decrease in Left Ventricular Ejection Fraction (LVEF).